Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | BCL9 | O00512 | 17/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 17/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258387 | 1.00 | REN (0.53) | RENBCL9CTNNB1ROCK2 | |
| SCHEMBL31258376 | 0.83 | CTNNB1 (0.51) | BCL9CTNNB1ROCK2 | |
| SCHEMBL31258373 | 0.83 | CTNNB1 (0.54) | BCL9CTNNB1ROCK2 | |
| SCHEMBL31258391 | 0.81 | BCL9 (0.47) | BCL9CTNNB1ROCK2 | |
| SCHEMBL31258379 | 0.80 | REN (0.58) | RENBCL9CTNNB1 | |
| SCHEMBL31258390 | 0.78 | HTR2C (0.51) | BCL9CTNNB1ROCK2 | |
| SCHEMBL24824301 | 0.74 | BCL9 (0.76) | BCL9CTNNB1 | |
| SCHEMBL13625495 | 0.74 | SLC6A2 (0.60) | REN | |
| Hydrochloric Acid SCHEMBL23124929 | 0.73 | BCL9 (0.77) | BCL9CTNNB1 | |
| SCHEMBL24872977 | 0.72 | REN (0.57) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
| WO-2023280177-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION | 南通聚太生物科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | REN 1371/4885BCL9 1/4885CTNNB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.